Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04106167
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : October 19, 2021
Information provided by (Responsible Party):
Fate Therapeutics

Brief Summary:

Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study.

The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

Condition or disease Intervention/treatment
Advanced Solid Tumor Lymphoma Gastric Cancer Colorectal Cancer Head and Neck Cancer Squamous Cell Carcinoma EGFR Positive Solid Tumor HER2-positive Breast Cancer Hepatocellular Carcinoma Small-cell Lung Cancer Renal Cell Carcinoma Pancreas Cancer Melanoma NSCLC Urothelial Carcinoma Cervical Cancer Microsatellite Instability Merkel Cell Carcinoma Genetic: Allogeneic natural killer (NK) cell

Detailed Description:
This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 76 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Actual Study Start Date : June 11, 2019
Estimated Primary Completion Date : February 2034
Estimated Study Completion Date : December 2037

Group/Cohort Intervention/treatment
Treatment with Fate Therapeutics' FT500 Cellular Immunotherapy
Long Term follow-up of subjects who have received an allogeneic, iPSC-derived NK cell in a previous trial.
Genetic: Allogeneic natural killer (NK) cell
No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy

Primary Outcome Measures :
  1. Overall Survival (OS) post-Infusion [ Time Frame: From the date of study entry until the date of documented death due to any cause, assessed up to 60 months. ]
    OS defined as the interval between the date of the first NK cell infusion and the date of death due to any cause

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with advance solid tumors rolling over from interventional study where they were treated with an allogeneic, iPSC-derived NK cell.

Inclusion Criteria:

  • Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study
  • Subjects who have provided Informed consent prior to their study participation

Exclusion Criteria:

  • Not Applicable

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04106167

Layout table for location contacts
Contact: Kimberly Musni (858) 875-1800
Contact: Karen Albers (858) 875-1800

Layout table for location information
United States, California
UCSD Moores Cancer Center Recruiting
San Diego, California, United States, 92093
United States, Minnesota
University of Minnesota Masonic Cancer Center Recruiting
Minneapolis, Minnesota, United States, 55455
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
Fate Therapeutics
Layout table for investigator information
Study Director: Jeff Chou, MD Fate Therapeutics
Layout table for additonal information
Responsible Party: Fate Therapeutics Identifier: NCT04106167    
Other Study ID Numbers: FT-003
First Posted: September 26, 2019    Key Record Dates
Last Update Posted: October 19, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Merkel Cell
Carcinoma, Renal Cell
Small Cell Lung Carcinoma
Pancreatic Neoplasms
Microsatellite Instability
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Urogenital Neoplasms
Kidney Neoplasms
Urologic Neoplasms
Kidney Diseases
Urologic Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Endocrine Gland Neoplasms